MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
– Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy…
METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
HONG KONG, May 14, 2026 /PRNewswire/ — METiS TechBio (7666.HK), a tech-bio…